Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma
机构：[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China[3]Eighth Peoples Hosp Guangzhou, Guangzhou, Guangdong, Peoples R China
出处：
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2014]版：
大类|1 区医学
小类|1 区血液学
最新[2023]版：
大类|1 区医学
小类|1 区血液学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Cai Qingqing,Chen Kailin,Geng Qirong,et al.Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma[J].BLOOD.2014,124(21):-.
APA：
Cai, Qingqing,Chen, Kailin,Geng, Qirong,Zhong, Guangzheng,Li, Jianping...&Li, Zhiming.(2014).Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma.BLOOD,124,(21)
MLA：
Cai, Qingqing,et al."Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma".BLOOD 124..21(2014):-
医学